Intrexon (XON) Tops Q1 EPS by 4c

Intrexon (NYSE: XON) reported Q1 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19).

“The landscapes of CAR-T therapies and the use of cytokines are playing out as anticipated,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “Regarding CAR-T, we find the dominating concern among patients, physicians and payers is the high costs and lengthy manufacturing time. We are addressing these issues head on with Sleeping Beauty CAR-T cells manufactured in two days with our technology called ‘point-of-care,’ which we expect to enter the clinic this year.”

Dr. Cooper continued, “Immune-stimulatory cytokines have gained significant momentum as potential combination therapies with immune checkpoint inhibitors. We are excited to build on our Controlled IL-12 platform and its ability to turn cold tumors hot as we explore more tumor types that can benefit from our ability to regulate IL-12.”

For earnings history and earnings-related data on Intrexon (XON) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc. (XP) Tops Q2 EPS by 8c
• KeyBanc Downgrades Kite Realty Group (KRG) to Sector Weight